This seminar series will provide updates on the diagnosis and treatment of chronic liver disease with a strong focus on patient care and symptom management. Teams of local, hepatology experts (physicians and advanced-practice providers) will deliver an interdisciplinary, team-based approach in a classroom setting that stresses interaction between participants and faculty.

To lower the barriers to participation and increase access, the program has been offered on Saturdays throughout the country beginning in December 2018.

The seminar will concentrate on key diseases of the liver and address the latest diagnosis, treatment and care management approaches for each.

**Primary Biliary Cholangitis (PBC)** is an old disease but one that is experiencing some major changes. A new treatment, Obeticholic Acid (OCA), the first new drug for the disease in 20 years, is a breakthrough for patients who have had an incomplete response to Ursodiol (URSO).

**Non-Alcoholic Steatohepatitis (NASH)** is an epidemic in the US and is expected to be the major cause of cirrhosis in the coming decades as chronic Hepatitis C quickly wanes. There are many unmet needs associated with NASH including simple biomarkers and other non-invasive tests to help diagnose it and promising therapies coming out of research trials. Also there are new breakthroughs in the treatment of Thrombocytopenia and NAFLD.

**End Stage Liver Disease (ESLD)** is expected to continue to grow in prevalence largely due to the burden of chronic viral hepatitis that exists in our population. As these patients age, a larger number will develop decompensation events such as variceal bleeding, hepatic encephalopathy, hyponatremia and renal failure.

**Hepatocellular Carcinoma (HCC)** is the most common form of liver cancer and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. HCC is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected. New research is yielding some promising therapies to treat and/or reduce tumor size.

**Thrombocytopenia and NAFLD.**

**Emerging Therapies for PBC, NASH, ESLD and HCC**

**PROGRAM HIGHLIGHTS**

- **End-Stage Liver Disease:** This program is especially developed for Hepatologists, Gastroenterologists, Internists, and Family Physicians as well as Advanced-practice Providers, Clinical Pharmacists and Nurse Specialists. These are the providers who are primarily tasked with caring for patients with chronic liver disease, both in the hospital and in the outpatient setting.

- **Updated content based on the latest medical guidelines and clinical trial results**

- **Strong patient-focused educational sessions using evidence-based studies from the latest AASLD, EASL and DDW programs**

- **Interactive format that includes practical patient care review, small group discussion and the use of Audience Response technology to gauge opinion and build consensus**

- **Teams of local experts, comprised of physicians and advanced-practice clinicians, providing an interdisciplinary, team approach to treatment**

- **Participants can receive up to 6.0 AMA PRA Category 1 Credits™ or up to 7.1 nursing education credits**

**WHO SHOULD ATTEND**

- **Providers** tasked with caring for patients with chronic liver disease, both in the hospital and in the outpatient setting.

**LOCATION & FACULTY**

**PASADENA, CA**
- Saturday, April 27
- Sheraton Pasadena
- Tse Ling Fong, MD
- USC Keck School of Medicine
- Sammy Saab, MD
- UCLA School of Medicine
- Lucy Mathew, ACNP-BC
- Cedars Sinai Medical Center

**DETROIT, MI**
- Saturday, June 1
- DoubleTree Hotel Dearborn
- Robert Fontana, MD
- University of Michigan Medicine
- Dilip Monika, MD
- Henry Ford Health System
- Jeffrey McMahon, PA-C
- Henry Ford Health System

**WASHINGTON, DC**
- Saturday, June 15
- Embassy Suites Alexandria Old Town
- Zobair Younossi, MD, MPH
- Inova Fairfax Hospital
- Kirti Shetty, MD
- University of Maryland School of Medicine
- Brian Lam, PA-C
- Inova Fairfax Hospital

**DENVER, CO**
- Saturday, June 22
- Embassy Suites Denver Tech Center North
- Marcello Kungalms, MD
- South Denver Gastroenterology
- Kurt Kulig, MD
- Porter Hospital Center for Liver Care
- Michelle R. Barnett, PA-C, DFAAPA
  - Partners in Gastroenterology

**RALEIGH, NC**
- Saturday, May 4
- Raleigh Marriott City Center
- Andrew Muir, MD
- Duke School of Medicine
- Sidney Barratt, IV, MD, MSCR
- UNC School of Medicine
- Elizabeth Goacher, PA-C
- UT Southwestern Medical Center

**ROCHELLE, IL**
- Saturday, June 15
- Embassy Suites Chicago O'Hare
- Jeffrey McMahon, PA-C
- South Chicago Hospital
- Brian Lam, PA-C
- Inova Fairfax Hospital

**FORT WORTH, TX**
- Saturday, June 22
- Embassy Suites Dallas
- Robert Fontana, MD
- University of Texas Southwestern Medical Center
- Michelle R. Barnett, PA-C, DFAAPA
  - Partners in Gastroenterology

**BEAUMONT, TX**
- Saturday, July 6
- Embassy Suites Beaumont
- Jeffrey McMahon, PA-C
- Beaumont Gastroenterology
- Brian Lam, PA-C
- Inova Fairfax Hospital

**DALLAS, TX**
- Saturday, July 13
- Embassy Suites Dallas-Plano
- Robert Fontana, MD
- University of Texas Southwestern Medical Center
- Michelle R. Barnett, PA-C, DFAAPA
  - Partners in Gastroenterology

**WASHINGTON, DC**
- Saturday, June 22
- Embassy Suites Denver Tech Center North
- Marcello Kungalms, MD
- South Denver Gastroenterology
- Kurt Kulig, MD
- Porter Hospital Center for Liver Care
- Michelle R. Barnett, PA-C, DFAAPA
  - Partners in Gastroenterology

**WHO SHOULD ATTEND**

- **Providers** tasked with caring for patients with chronic liver disease, both in the hospital and in the outpatient setting.

**DON'T MISS OUT ON THIS NATIONAL PROGRAM COMING TO A CITY NEAR YOU!**
EDUCATIONAL OBJECTIVES

After attending this activity, participants should be able to:

- Summarize the causes of chronic liver disease and hepatic encephalopathy
- Comprehend the complexities of organ transplant procedures and waitlists
- Review the current therapies for PBC and clinical approaches for PSC
- Learn about diagnostic tests for NASH that may soon be in daily use
- Discuss the importance of liver biopsy for assessment of liver disease as well as less invasive tools and procedures
- Integrate newer treatment options for HCC as well as approaches to reduce tumor size and number
- Discover why immunotherapy is the new Method of Action for Hepatocellular Carcinoma
- Discuss treatment options for thrombocytopenia, including therapeutic alternatives to platelet transfusion
- Identify the progression pathways of Fatty Liver Disease to NASH to Liver Cancer to improve patient management processes and clinical outcomes
- Utilize current clinical cases to improve diagnostic and treatment skills

COURSE DIRECTORS

Paul Pockros, MD, FACC
Director, Liver Disease Center Scripps Clinic

Catherine Ferrante, MD
Medical Director for Liver Transplantation Scripps Center for Organ and Cell Transplantation

Registration Information

Early Registration Regular Registration
Physicians and Clinical Pharmacists $95 $115
Nurses, Nurse Practitioners and PAs $70 $90
Medical Residents & Fellows $60 $80

Or call: University of Louisville CME & PD (502) 852-5329

DISCLOSURE

Commercial Support
This course is supported, in part, by educational grants from industry, in accordance with ACCME Accreditation Standards. For a clear disclosure of commercial support, all relevant financial relationships with any commercial supporter must be disclosed and approved. The ACCME recognizes the importance of providing disclosure information to participants and takes measures to mitigate any conflicts of interest. All faculty must receive appropriate approval to participate in this course.

Faculty Disclosure
The University of Louisville complies with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial entity that, in the judgement of the activity leader, could influence the activity.

The mission of the University of Louisville Continuing Medical Education and Professional Development program is to facilitate the needs of physicians and other healthcare team members as they seek self-improvement through life-long learning. For more information visit http://louisville.edu/medicine/cme

The SC Liver Research Consortium (SCLRC) is an organization of physicians specializing in hepatology and gastroenterology clinical research. SCLRC’s mission is to team research sponsors and SCLRC’s over 90 research sites together to provide faster, higher-quality research results compared to the current “conventional” sponsor-site arrangement. For more information visit www.scliver.com

ACREDITATION

Joint Provider Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville School of Medicine and SC Liver Research Consortium. The University of Louisville School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement
Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.1 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1085. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners & Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)™ organizations accredited by ACCME.

SPONSORS

Scripps Clinic and Upper Midwest Regional Transplant Network